23 September 2026
Table of Contents
For a long time, immunotherapy was thought of as a later-stage option — something considered after chemotherapy or other treatments hadn’t worked. Here’s the honest answer: that’s changed significantly. For a number of specific cancers, immunotherapy is now used as the very first treatment a patient receives, not a backup plan.
Let’s walk through this together. This guide explains how that shift happened, which cancers it applies to, and how your care team decides whether first-line immunotherapy is right for your specific situation.
The Traditional Order of Cancer Treatment
Historically, cancer treatment often followed a fairly predictable sequence: surgery where possible, followed by chemotherapy and radiation, with newer treatments like immunotherapy reserved for cases where the cancer returned or didn’t respond to these standard approaches.
This order made sense at the time because chemotherapy and radiation had the strongest track record, and immunotherapy was newer, with less established evidence for its use earlier in treatment.
How Immunotherapy Earned a First-Line Role
As clinical trials accumulated years of data, a clear pattern emerged for certain cancers: patients who received immunotherapy earlier, sometimes even before any other treatment, had outcomes as good as or better than those who received it only after other options were exhausted.
KEY FACT
“First-line treatment” simply means the first treatment offered for a specific cancer diagnosis. For an increasing number of cancer types, clinical trial evidence now supports immunotherapy, sometimes alone and sometimes combined with chemotherapy, in that first-line role.
This shift didn’t happen overnight or across the board — it’s specific to particular cancer types and, often, to patients whose tumours show certain biological markers that predict a strong response to immunotherapy.
Which Cancers Commonly Use First-Line Immunotherapy
First-line immunotherapy is now well established for several cancer types, including certain lung cancers, melanoma, some kidney cancers, and select cases of advanced or recurrent cervical cancer, often combined with chemotherapy. The specific role varies by cancer type, stage, and individual tumour characteristics.
How Doctors Decide If You're a Candidate
Whether immunotherapy is appropriate as a first treatment depends on several factors your oncology team will assess together:
- Cancer type and stage. First-line immunotherapy is established for specific cancer types and stages — it isn’t a universal first option across all cancers.
- Biomarker testing. Tumour tissue is often tested for markers such as PD-L1 expression, which help predict how likely a patient is to respond well to immunotherapy.
- Overall health. Because immunotherapy affects the immune system broadly, your general health and any autoimmune conditions are factored into the decision.
- Available clinical evidence. Your oncologist will weigh the strength of evidence specifically supporting first-line use for your exact diagnosis.
What the Process Looks Like as a First Treatment
If immunotherapy is recommended as your first treatment, the process itself doesn’t look dramatically different from immunotherapy used at any other stage — typically IV infusions on an outpatient basis, spaced a few weeks apart, sometimes alongside chemotherapy, with regular scans and blood tests to track response.
What’s different is the sequencing: you may not go through chemotherapy or radiation first, or you may receive immunotherapy alongside them from the outset, depending on your specific treatment plan.
Benefits and Cautions to Weigh
IMPORTANT
Immunotherapy’s side effects differ from chemotherapy’s — they relate to immune system activation rather than broad cell damage. Used first-line doesn’t change the nature of these side effects, so the same monitoring for immune-related reactions applies from the start of treatment.
For eligible patients, first-line immunotherapy can mean avoiding or delaying some of the more broadly toxic effects of chemotherapy. It isn’t automatically the gentler option for everyone, though — your oncologist can walk you through how the specific risks and benefits apply to your case.
First-Line Approaches Compared
Approach | How It Works | When It’s Used |
Traditional order | Chemotherapy or surgery first; immunotherapy considered later if needed | Cancers without strong first-line immunotherapy evidence |
Immunotherapy first | Immunotherapy given as the initial treatment | Specific cancers and markers with established first-line evidence |
Combination first-line | Immunotherapy and chemotherapy given together from the start | Select advanced or recurrent cancers, including some cervical cancers |
Frequently Asked Questions
Not always. For some cancers, immunotherapy is given alone first-line; for others, it's combined with chemotherapy from the outset. Your specific plan depends on your diagnosis and tumour characteristics.
For most cancers where first-line immunotherapy is considered, yes — testing markers like PD-L1 expression helps your oncologist assess how likely you are to benefit.
Generally yes. Using immunotherapy first-line doesn't usually close off other treatment options if a change in approach becomes necessary.
No, it's typically established for specific stages, often locally advanced, recurrent, or metastatic disease, depending on the cancer type. Your oncologist can clarify whether it applies to your specific stage.
This is a direct and worthwhile question to raise with your treating oncologist, who can explain the current evidence and guidelines specific to your diagnosis.
The nature of the side effects doesn't change based on when immunotherapy is given — they relate to immune activation either way. Your care team monitors for them consistently regardless of treatment sequencing.
A Final Word
Learning that immunotherapy might be your first treatment, rather than something held in reserve, can feel like unfamiliar territory if you were expecting a more traditional treatment path. What this means for you is that this shift reflects genuine, hard-won clinical evidence — for the right cancers and the right patients, starting with immunotherapy has measurably improved outcomes.
If you’d like to understand whether first-line immunotherapy could apply to your specific diagnosis, speaking with a gynaecologic oncologist is the best next step to get a clear, individualised answer.
